| Project/Area Number |
25462168
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cardiovascular surgery
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
荻野 均 東京医科大学, 医学部, 主任教授 (60393237)
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 人工血管 / フィブロネクチン / ヘパリン / 共有結合 / 共有結合固定 / 組織工学 / 共有結語固定 |
|---|
| Outline of Final Research Achievements |
Tissue engineering has emerged as a promising approach to generate biologically functioning prosthetic vascular grafts exhibiting rapid neointima formation without subsequent degenerative change. We demonstrated that, in a canine model, covalent bonding of fibronectin enhanced the healing of small-caliber, long-fibril ePTFE vascular grafts. However, in a pig model, the fibronectin-bonded grafts did not exhibit powerful antithrombogenicity by the luminal endothelial cells until graft healing was completed, and therefore subsequent graft thrombosis occurred. We therefore hypothesized that, with further modifications by an anti-thrombotic molecule coating, covalent bonding of fibronectin may have great potential in the development of better small-caliber arterial prosthetic grafts.We could determine the optimal condition of covalent-bonding of fibronectin as well as heparin, and are continuing to develop the optimal method of simultaneous covalent-bonding of fibronectin and heparin.
.
|
